Verona Pharma plc (VRNA)

NASDAQ: VRNA · IEX Real-Time Price · USD
16.09
-0.41 (-2.48%)
At close: Mar 28, 2024, 4:00 PM
16.65
+0.56 (3.48%)
After-hours: Mar 28, 2024, 7:41 PM EDT

Company Description

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.

The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler.

Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Verona Pharma plc
Verona Pharma logo
Country United Kingdom
Founded 2005
IPO Date Apr 27, 2017
Industry Biotechnology
Sector Healthcare
Employees 79
CEO Dr. David S. Zaccardelli Pharm.D.

Contact Details

Address:
3 More London Riverside
London, X0 SE1 2RE
United Kingdom
Phone 011-44-0-2032834200
Website veronapharma.com

Stock Details

Ticker Symbol VRNA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001657312
CUSIP Number 925050106
ISIN Number US9250501064
SIC Code 2834

Key Executives

Name Position
Dr. David S. Zaccardelli Pharm.D. President, Chief Executive Officer and Executive Director
Mark W. Hahn Chief Financial Officer
Dr. Kathleen A. Rickard M.D. Chief Medical Officer
Victoria Stewart Director of Communications
Matthew Casbon Vice President of Sales, Marketing and Training
Ostra Jewell Senior Vice President of Human Resources
Dr. Tara Rheault M.P.H., Ph.D. Chief Development Officer
Christopher Martin Chief Commercial Officer
Caroline Diaz Senior Vice President of Regulatory Affairs
Dr. Kavita Aggarwal Senior Vice President of Medical Affairs

Latest SEC Filings

Date Type Title
Mar 20, 2024 ARS Filing
Mar 20, 2024 DEF 14A Other definitive proxy statements
Mar 12, 2024 144 Filing
Mar 8, 2024 PRE 14A Other preliminary proxy statements
Mar 4, 2024 144 Filing
Feb 29, 2024 10-K Annual Report
Feb 29, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals